ABU DHABI, 2nd February, 2023 (WAM) — Insilico Medicine, a scientific-stage synthetic intelligence (AI)-driven drug discovery firm, at this time introduced the opening of the Insilico Medicine Generative Synthetic Intelligence and Quantum Computing Research and Growth Centre in Abu Dhabi, the area’s largest AI-powered biotechnology analysis centre.
Positioned in the Worldwide Renewable Power Agency (IRENA) headquarters in Masdar Metropolis, Abu Dhabi’s flagship sustainable city growth, the analysis and growth (R&D) hub will comprise world expertise in synthetic intelligence and software program growth devoted to increasing the capabilities of Insilico’s finish-to-finish AI-pushed drug discovery platform, Pharma.AI, exploring getting old analysis and sustainable chemistry, and supporting the digital transformation of healthcare in the area.
The grand opening occurred on the IRENA headquarters atrium in Masdar Metropolis, witnessed by practically 100 ecosystem companions from the federal government, academia, the funding neighborhood, and the AI and biotech business. The occasion featured speeches from Omar bin Sultan Al Olama, Minister of State for Synthetic Intelligence, Digital Economic system, and Distant Work Purposes, Alex Zhavoronkov, PhD, Founder and CEO of Insilico, and Alex Aliper, PhD, President of Insilico.
“The prime location, strong and stable economy, developed infrastructure, and highly educated talent make Abu Dhabi an emerging hub that attracts high-tech companies from around the world. We are excited to be a part of this,” mentioned the President of Insilico, who will function the regional hub’s normal supervisor. “We plan to hire locally and work closely with biotech companies and academic partners to license Insilico’s proprietary software and collaborate on joint research projects to facilitate the digital transformation of the local healthcare industry.”
“This is exactly the kind of groundbreaking work in artificial intelligence that we aim to support in our free zone and innovation ecosystem,” mentioned Ahmed Baghoum, Performing CEO of Masdar Metropolis. “We’re excited about this milestone for Insilico Medicine — particularly given it is taking place during the Year of Sustainability. We look forward to the transformational research that will come out of this incredible new hub. We thank the Abu Dhabi Investment Office for attracting these organisations to Masdar City.”
Insilico has made regular inroads into the Middle East. On thirty first January 2023, the corporate introduced that it’s going to obtain help from the Abu Dhabi Funding Workplace (ADIO) to determine its regional HQ in Abu Dhabi targeted on R&D for its AI platform.
Abdulla Abdul Aziz AlShamsi, ADIO Performing Director-Common, mentioned, “ADIO congratulates Insilico Medicine on opening a regional HQ in the UAE capital. Abu Dhabi has prioritised advancing technological solutions that further economic progress for the region and beyond. Insilico Medicine is a stellar example of the success of that strategy, and proof of the limitless opportunities available for health tech companies in Abu Dhabi.”
In August 2022, the corporate introduced a Sequence D2 funding led by Prosperity7 Ventures, the diversified progress fund of Aramco Ventures, increasing its AI biotechnology experience into Saudi Arabia. The corporate additionally signed a Memorandum of Understanding with the Ministry of Funding of Saudi Arabia, which incorporates offering Insilico’s finish-to-finish AI drug discovery platform to native biotech corporations, partnering with native biotechs on robotic drug discovery, contributing to native scientific trial experience, and additional growing initiatives extending wholesome and productive longevity.
Insilico founder and CEO Alex Zhavoronkov, PhD, was additionally a featured speaker on the World AI Summit in Riyadh, Saudi Arabia, in Sept. 2022, an occasion targeted on AI for the nice of humanity.
“Since our very inception, our mission has been to extend healthy, productive longevity for everyone on the planet. Over the past decade, we developed a platform for drug discovery and longevity and became one of the dominant companies in this field. Now, we would like to extend our global infrastructure to the Middle East,” mentioned Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. “We look forward to expanding our presence and connections in the region by creating a true AI drug discovery hub in Abu Dhabi.”